Sentiment: Strong Buy
It should be taking place right now...
Abstract Number: LB-166
Presentation Title: Cabozantinib (cabo) + abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): preclinical evaluation and interim results of an investigator-sponsored phase 1 clinical study.
Presentation Time: Tuesday, Apr 09, 2013, 8:00 AM -12:00 PM
Location: Hall A-C, Poster Section 47
Author Block: Christopher J. Sweeney, Katherine Zukotynski, Xiaodong Wang, Andrew Wick, Amanda Fredericks, Bon Lam, Philip Kantoff. Dana Farber Cancer Inst., Boston, MA
I wonder what time the interm results will start leaking out.